ѧÊõÌÃÊ×Ò³ | ÎÄÏ×ÇóÖúÂÛÎÄ·¶ÎÄ | ÂÛÎÄÌâÄ¿ | ²Î¿¼ÎÄÏ× | ¿ªÌⱨ¸æ | ÂÛÎĸñʽ | ÕªÒªÌá¸Ù | ÂÛÎÄÖÂл | ÂÛÎIJéÖØ | ÂÛÎÄ´ð±ç | ÂÛÎÄ·¢±í | ÆÚ¿¯ÔÓÖ¾ | ÂÛÎÄд×÷ | ÂÛÎÄPPT
ѧÊõÌÃרҵÂÛÎÄѧϰƽ̨Äúµ±Ç°µÄλÖãºÑ§ÊõÌà > ÉúÎïѧÂÛÎÄ > Éñ¾­ÉúÎïѧÂÛÎÄ

Å®ÐÔÂýÐÔÅèǻʹµÄ·¢Éú»úÖÆÑо¿×ÛÊö

À´Ô´£º¹ú¼Ê¸¾²ú¿ÆѧÔÓÖ¾ ×÷ÕߣºÁõÑÞÃô;½­ÐãÐã
·¢²¼ÓÚ£º2019-02-26 ¹²8996×Ö

¡¡¡¡Õª    Òª£º¡¡ÅèǻʹÊÇÅ®ÐÔ³£¼û¸¾¿Æ¼²²¡Ö®Ò», ÒÔÂýÐÔÅèǻʹΪÖ÷, ¶ÔÅ®ÐÔµÄ×ËÊÆ¡¢Æ½ºâÄÜÁ¦µÈ¶¼ÓÐ׎ϴóµÄÓ°Ïì, ÑÏÖØÍþв×ÅÅ®ÐÔ»¼ÕßµÄÉú»îÖÊÁ¿ºÍÉúÃü½¡¿µ¡£µ«ÊÇÄ¿Ç°¹ØÓÚÅ®ÐÔÂýÐÔÅèǻʹ·¢ÉúµÄÉúÎïѧ»ù´¡Éв»Çå³þ, ²¡ÒòÒ²Éв»Ã÷È·, ÇÒ¶ÔÂýÐÔÅèǻʹµÄÆÀ¹ÀºÍÖÎÁÆÒ²±È½Ï¸´ÔÓ, ¸øÅ®ÐÔÂýÐÔÅèǻʹµÄÖÎÁƺͿµ¸´´øÀ´Á˽ϴóµÄÀ§ÄÑ¡£ÎªÁ˸øÅ®ÐÔÅèǻʹԤ·ÀºÍÖÎÁÆÌṩ½øÒ»²½µÄÀíÂÛ»ù´¡, Äâ¶ÔÅ®ÐÔÄÚÉúֳϵͳºÍÍâÉúֳϵͳµÄÉñ¾­Ö§Åä¡¢ÖÐÊàÉñ¾­ÏµÍ³Ó°Ïñ¸Ä±äºÍÌÛÍ´Ò׸ÐÐÔ¡¢Ï¸°ûÒò×ÓºÍÍâÖÜÉñ¾­ÏËάµÄÏ໥×÷Óá¢Ñ×Ö¢Òò×ÓÔÚ½µµÍÍâÖÜÉñ¾­Ãô¸ÐÐÔÖеÄ×÷Óá¢ÄÆÀë×ÓͨµÀ½éµ¼Éñ¾­ÔªÌÛÍ´ÐźŵĴ«µ¼¡¢Éñ¾­ÔªµÄ¼¤Ã¸ÐźŴ«µ¼Í¨Â·¼¤»î½øÐÐ×ÛÊö, Öصã̽ÌÖÐźÅͨ·ºÍϸ°ûÒò×ÓµÈÒòËØÔÚÌÛÍ´·¢ÉúÖеÄ×÷Óá£

¡¡¡¡¹Ø¼ü´Ê£º¡¡¹ÇÅèÍ´; Éñ¾­ÉúÎïѧ; ÐźŴ«µ¼; ϸ°ûÒò×ÓÀà; ¼²²¡Ò׸ÐÐÔ;

¡¡¡¡Abstract£º¡¡Pelvic pain is one of the common gynecological diseases in women, which mainly presents as chronic pelvic pain. It has not only a great impact on women′s posture and balance ability, but also severe influence on the quality of life and health. However, the biological basis and etiology of chronic pelvic pain are still unclear. Its evaluation and treatment are complicated, which brings great difficulties to the treatment and rehabilitation. We aim to review the innervation of internal and external reproductive systems, the imaging changes and pain susceptibility of central nervous, the interaction between cytokines and peripheral nerve fibers, the role of inflammation factor in reducing peripheral nerve sensitivity, the pain signals transmission and neurons kinase signaling pathways activation mediated by sodium channel to further provide a theoretical basis for the prevention and treatment of female pelvic pain. We focus on the role of signaling pathways and cytokines in the pathogenesis of pain.

¡¡¡¡Keyword£º¡¡Pelvic pain; Neurobiology; Signal transduction; Cytokines; Disease susceptibility;

¡¡¡¡Åèǻʹ (pelvic pain) ÊÇÅ®ÐÔ³£¼ûµÄ¸¾¿Æ¼²²¡Ö®Ò», ·ÖΪ¼±ÐÔÅèǻʹºÍÂýÐÔÅèǻʹ (chronic pelvic pain, CPP) [1], ÒÑÊܵ½È«ÇòÐԵĹ㷺¹Ø×¢¡£Ôì³ÉÅèÇ»ÌÛÍ´µÄ¸¾¿Æ³£¼û²¡Òò°üÀ¨×Ó¹¬ÄÚĤÒìλ֢¡¢¸÷ÖÖ¸¾¿ÆÖ×Áö¡¢¸¾¿ÆÑ×Ö¢ÒÔ¼°ÅèÇ»ÓÙѪ×ÛºÏÕ÷µÈ¡£¼±ÐÔÅèǻʹÆ𲡽ϼ±, ÁÙ´²±íÏÖ¶àµäÐÍ, Ò»°ãÒ×Õï¶Ï, ¿ÉÔÚ¶ÌÆÚÄÚÖÎÓú, ¶øÂýÐÔÅèǻʹĿǰ²¡ÒòÉÐδÃ÷È·, ²¡Òò½ÏΪ¸´ÔÓ, ¿ÉÓɶàÖÖÒòËØ×ۺϵ¼ÖÂ, ²¡³Ì½Ï³¤[2]¡£Ñо¿±íÃ÷ÔÚÍ´¾­¡¢·ÇÖÜÆÚÐÔ¹ÇÅèÍ´¡¢ÐÔ½»À§ÄÑ¡¢ÅÅÄòÀ§ÄÑÒÔ¼°´ó±ãÀ§ÄÑÕâ5ÖÖÌÛÍ´ÈËȺÖÐ, ÅèÇ»ÌÛÍ´µÄ³Ì¶ÈÓëÌÛÍ´ÔÖÄÑ»¯Á¿±í·ÖÊýÖ®¼ä³ÊÕýÏà¹Ø[3]¡£ÂýÐÔÅèǻʹ¶ÔÅ®ÐÔΣº¦½Ï´ó, ÓÐÑо¿±íÃ÷Å®ÐÔ»¼ÓÐÂýÐÔÅèǻʹ¶ÔÆäƽºâÄÜÁ¦ÒÔ¼°×ËÊƶ¼ÓÐÒ»¶¨µÄÓ°Ïì[4]¡£ÆÀ¹ÀºÍÖÎÁÆÂýÐÔÅèǻʹÊÇÒ»¸ö¸´ÔÓµÄÎÊÌâ, Éæ¼°µ½Î¸³¦²¡¡¢ÃÚÄò¿Æ¡¢¸¾¿Æ¡¢Ö×Áö¡¢¼¡Èâ¹Ç÷ÀºÍÉç»áÐÄÀíµÈÒòËØ, ²¡Çé±È½Ï¸´ÔÓ, ºÜÄÑÖÎÁÆ[5]¡£ÎªÁ˸øÂýÐÔÅèǻʹµÄÖÎÁƺÍÔ¤·ÀÌṩ½øÒ»²½µÄÀíÂÛÖ§³Ö, ÏÖ¶ÔÂýÐÔÅèǻʹµÄһЩÉñ¾­ÉúÎïѧ»ù´¡µÄÑо¿½øÕ¹½øÐÐ×ÛÊö¡£

¡¡¡¡1 Å®ÐÔÉúֳϵͳµÄÉñ¾­ÉúÎïѧ»ù´¡

¡¡¡¡Éñ¾­ÏµÍ³¿ÉÒÔ½«ÐźŴ«µÝÖÁÉíÌå¸÷¸ö×éÖ¯Æ÷¹Ù, ÓÖ½ÓÊÜÀ´×Ô×éÖ¯Æ÷¹ÙµÄ·´À¡ÐÅÏ¢, ´Ó¶øµ÷½Ú×éÖ¯Æ÷¹ÙµÄÕý³£»î¶¯, ÆäÖаüÀ¨×Ó¹¬ºÍÂѳ²µÈÅ®ÐÔÉúֳϵͳÏà¹ØÆ÷¹ÙºÍ×éÖ¯¡£Éñ¾­ÏµÍ³ºÍÆ÷¹ÙÖ®¼äÄÜÏ໥µ÷½ÚºÍÖÆÔ¼, ͨ¹ý·´À¡ºÍ¸º·´À¡»úÖÆά³ÖƽºâºÍÕý³£, ʹŮÐÔÄÚ·ÖÃÚ±£³ÖÎȶ¨, ÆäÖÐÈκÎÒ»¸ö²¿·Ö·¢ÉúÎÉÂÒ»ò²¡±ä, ¶¼»áµ¼ÖÂÅ®ÐÔÉúֳϵͳ¹¦ÄÜÎÉÂÒ, ÒýÆðÄÚ·ÖÃÚ¼²²¡, ±íÏÖΪ¸¾¿ÆÌÛÍ´¡¢Ô¾­Ê§µ÷¡¢³öѪºÍ²»Ôеȡ£

Å®ÐÔÂýÐÔÅèǻʹµÄ·¢Éú»úÖÆÑо¿×ÛÊö

¡¡¡¡ÔÚ¸¾²ú¿ÆÁìÓòÖÐ, ÓÐÁ½ÖÖÉñ¾­Æð׎ÏΪÖØÒªµÄµ÷½Ú¹¦ÄÜ, ·Ö±ðΪ½»¸ÐÉñ¾­ºÍ¸±½»¸ÐÉñ¾­¡£ºÜ¶à¸¾²ú¿Æ¼²²¡²»µ¥´¿ÊÇÄÚ·ÖÃÚÕÏ°­ÒýÆðµÄ, Ö²ÎïÐÔÉñ¾­ÏµÍ³Ò²¿ÉÄÜ·¢ÉúÁ˸ı䡣ŮÐÔµÄÊäÂѹܡ¢ÒõµÀ¡¢×Ó¹¬µÈÄÚÉúÖ³Æ÷µÄÖ§ÅäÉñ¾­ÓÐÁ½ÖÖ, Ò»ÖÖΪ½»¸ÐÉñ¾­, ÁíÒ»ÖÖΪ¸±½»¸ÐÉñ¾­, Ç°ÕßÔÚÅèÇ»ÖÐÖ÷Òª°üº¬Á½ÖÖÀàÐÍ, Ê×ÏÈÊÇÂѳ²Éñ¾­´Ô, ÆäÖ÷ÒªµÄ·Ö²¼·¶Î§ÎªÂѳ²ºÍÊäÂѹÜ, ÁíÍâÒ»ÖÖÀàÐÍΪ÷¾Ç°Éñ¾­´Ô, ¸ÃÉñ¾­´ÔµÄ´ó²¿·ÖÖ÷ÒªÊÇÔÚ¹¬¾±ÅÔ, ÔÚ´Ë´¦ÐγÉÁ˹ÇÅèÉñ¾­´Ô, ÆäÖ÷ÒªµÄ·Ö²¼·¶Î§Î»ÓÚ×Ó¹¬µÄ¹¬¾±ºÍ¹¬Ì岿·ÖÒÔ¼°°òë×µÄÉϲ¿µÈ;¸±½»¸ÐÉñ¾­µ½´ï¹ÇÅèÉñ¾­´Ô, ÓÉ´Ë·ÖÖ§µ½´ïÊäÂѹܡ¢×Ó¹¬µÈ¡£Å®ÐÔÉúÖ³Æ÷Êܵ½½»¸ÐÉñ¾­ºÍ¸±½»¸ÐÉñ¾­µÄÖ§Åä, ·´Ö®½»¸ÐÉñ¾­ºÍ¸±½»¸ÐÉñ¾­Ò²Ã÷ÏÔÊÜÂѳ²¼¤ËصÄÓ°Ïì¡£¸¾²ú¿ÆÁìÓòÖг£¼ûµÄÌÛÍ´Àà±ð¡¢ÌÛÍ´ÌصãÒÔ¼°ËùÖ§ÅäµÄÉñ¾­¾ßÌå¼û±í1¡£

¡¡¡¡1.1 ÄÚÉúÖ³Æ÷¹ÙµÄÉñ¾­Ö§Åä

¡¡¡¡ÄÚÉúÖ³Æ÷¹ÙµÄÉñ¾­Ö§Åä°üÀ¨½»¸ÐºÍ¸±½»¸Ð, Á½Õß¾ùΪ×ÔÖ÷Éñ¾­, Ç°ÕßÖ÷ÒªÊÇÔÚÖ÷¶¯Âö´ÔÖзֳö, Õâ¸öÖ÷¶¯Âö´ÔÖ÷ҪλÓÚ¸¹Ö÷¶¯Âö, Ö÷¶¯Âö´ÔµÄһЩÏËάÓÖ¿ÉÒÔ¼ÌÐøÐγÉÂѳ²´ÔºÍ÷¾Ç°´Ô, Ç°Õß·Ö²¼ÓÚ»úÌåµÄÂѳ²¼°ÊäÂѹÜ, ºóÕß·Ö²¼ÓÚ»úÌåµÄ×Ó¹¬¡¢Ö±³¦¼°°òëס£ÔÚ»úÌå³öÏÖ²¡Àí״̬µÄÇé¿öÏÂ, ÅèÇ»ÄÚµÄÄÚÔàÈç¹û·¢ÉúÌÛÍ´»òÕßƽ»¬¼¡¾·Âη¢ÉúµÄÌÛÍ´¶¼ÊÇÓÉÓëÅèÇ»½»¸ÐÉñ¾­°éÐеIJ¿·ÖÄÚÔà¸Ð¾õÉñ¾­½øÐд«µÝ¡£

¡¡¡¡1.2 ÍâÉúÖ³Æ÷¹ÙµÄÉñ¾­Ö§Åä

¡¡¡¡»úÌåµÄÍâÉúÖ³Æ÷¹ÙÒ²ÓÐÉñ¾­Ö§Åä, Ö÷ҪΪÒõ²¿Éñ¾­, ÆäÀ´Ô´½Ï¶à, Ê×ÏÈÊÇ÷¾´Ô·ÖÖ§, Æä´ÎÊÇ×ÔÖ÷Éñ¾­, Ö÷Òª°üÀ¨µÚ¢ñ¡¢¢ò¡¢¢ô÷¾Éñ¾­µÄ·ÖÖ§, Ò²°üÀ¨Á½ÖÖÉñ¾­ÏËά, ÆäһΪ¸Ð¾õÉñ¾­ÏËά, Æä¶þΪÔ˶¯Éñ¾­ÏËά¡£Òõ²¿Éñ¾­ÓëÒõ²¿ÄÚ¶¯ÂöÖ®¼ä²¢ÐÐ, È»ºóÔÚ×ø¹Ç½á½ÚÄÚ·ÖÓÚ3´¦, ·Ö±ðΪÖÌÏ¡¢ÒõµÙ±³¼°»áÒõÉñ¾­, Õâ3ÖÖÉñ¾­·Ö±ð·Ö²¼ÓÚ¸ØÃÅ¡¢ÒõµÙ±³¼°»áÒõ²¿¡£

¡¡¡¡½»¸ÐÉñ¾­ºÍ¸±½»¸ÐÉñ¾­ÊÇÅ®ÐÔÄÚÉúÖ³µÀµÄÁ½ÖÖÖ÷ÒªÉñ¾­, ÔÚÅ®ÐÔÉúֳϵͳµÄÉúÀí¹¦ÄÜ·½Ãæ·¢»Ó×ÅÖØÒªµÄ×÷Óá£

¡¡¡¡2 Å®ÐÔÅèǻʹµÄÒ׸ÐÐÔ

¡¡¡¡2.1 ÖÐÊàÉñ¾­ÏµÍ³Ó°Ïñ¸Ä±äºÍÌÛÍ´Ò׸ÐÐÔ

¡¡¡¡Ä¿Ç°Ò»Ð©Ó°Ïñѧ¼ì²éÊֶΰüÀ¨Õýµç×Ó·¢Éä¶Ï²ãɨÃè (PET) ÒÔ¼°¹¦ÄÜÐԴŹ²Õñ³ÉÏñ (fMRI) ¾ùÒѱíÃ÷»úÌåÄÔ²¿ÌÛÍ´´¦ÀíÇøµÄ¹¦ÄÜ·¢Éú¸Ä±ä¿ÉÄܻᵼÖ»úÌå²úÉú²»Ã÷Ô­ÒòµÄÂýÐÔÌÛÍ´¡£

¡¡¡¡Å®ÐÔÂýÐÔÅèǻʹÊÇÓɺܶàÖÖÔ­Òò×ۺϵ¼ÖµÄ, Ϊ³ÖÐøÐÔ»òÕß·ÇÖÜÆÚÐÔµÄÌÛÍ´, ÆäÌÛÍ´µÄ³ÖÐøʱ¼äÒ»°ãΪ6¸öÔÂ[6]¡£ÓÐÑо¿·¢ÏÖÔ¼15%µÄÅ®ÐÔ»¼ÓÐÂýÐÔÅèǻʹ[7]¡£ºÜ¶à¼²²¡ÓëÂýÐÔÅèǻʹÓйØ, ÈçÂýÐÔÅèÇ»Ñ×ÐÔ¼²²¡[8]¡¢¼äÖÊÐÔ°òë×Ñ× (interstitial cystitis, IC) [9]¡¢×Ó¹¬ÄÚĤÒìλ֢ (EMs) [10]¡¢°òë×ÌÛÍ´×ÛºÏÕ÷ (painful bladder syndrome, PBS) [11]¡¢×Ó¹¬ÏÙ¼¡²¡[12]¡¢³¦Ò×¼¤×ÛºÏÕ÷ (irritable bowelsyndrome, IBS) [13]µÈ¡£Ñо¿·¢ÏÖ, ÓëÆäËûÂýÐÔÌÛÍ´»¼ÕßÏàËÆ, ÂýÐÔÅèǻʹ»¼ÕßµÄÖÐÊàÉñ¾­ÏµÍ³Ò²»áÓÐÒ»¶¨µÄ±ä»¯, Ö÷ÒªÌåÏÖÔڽṹÉϺ͹¦ÄÜÉÏ¡£Ò»°ãÇé¿öÏÂ, ÖÐÊàÉñ¾­ÏµÍ³µÄÃô»¯ (central sensitization, CS) ÊÇÓÉÍâÖÜÉñ¾­ÏµÍ³Òý·¢, ²¢ËæÖ®Ïû³ý¶ø»º½â, È»¶øÔÚһЩ²¡ÀýÖÐCSºÍÍâÖÜÉñ¾­ÏµÍ³µÄ´Ì¼¤Ã»ÓÐÖ±½ÓÁªÏµ[14]¡£Óб¨µÀ·¢ÏÖÔÚһЩ×Ó¹¬ÄÚĤÒìλÒýÆðµÄÂýÐÔÅèǻʹŮÐÔ»¼ÕßÖÐ, ÄÔ²¿ÇøÓòµÄÓÀ¾Ã¸Ä±äÓëÌÛÍ´Óйء£2012ÄêAs-SanieµÈ[15]½«ÓÐÂýÐÔÅèǻʹµÄEMs»¼ÕߺÍûÓÐÂýÐÔÅèǻʹµÄEMs»¼Õß·Ö±ðÓëÕý³£ÈËȺ½øÐжԱÈ, ½á¹û·¢ÏÖÓÐÂýÐÔÅèǻʹµÄEMs»¼ÕßµÄÇðÄÔ¡¢¿Û´ø»Ø¡¢µºÒ¶µÈµÄƤÖʱ䱡, ¶øÎÞÂýÐÔÅèǻʹµÄEMs»¼Õߵĵ¼Ë®¹ÜÖÜΧ»ÒÖÊ (periaqueductal grey, PAG) Ìå»ýÓÐÔö´óµÄÏÖÏó, ÇÒÔö´óµÄ³Ì¶ÈÓ뻼Õ߶ÔÌÛÍ´µÄÄÍÊÜÐÔÖ®¼äΪÕýÏà¹ØµÄ¹Øϵ, ÍƲâPAG¾ßÓÐÄÚÔ´ÐÔÌÛÍ´ÒÖÖƵÄ×÷ÓÃ, Òò´Ë´ÓÖÎÁƽǶȿ´, ÏëÒªÍêÈ«¸ùÖÎCPP½ö½ö×ÅÑÛÓÚ²¡ÔîÑо¿ÊÇÍêÈ«²»¹»µÄ[16]¡£

¡¡¡¡±í1 ¸¾²ú¿ÆÁìÓòÖг£¼ûµÄÌÛÍ´Àà±ð¡¢ÌÛÍ´ÌصãÒÔ¼°Ö§ÅäÉñ¾­
±í1 ¸¾²ú¿ÆÁìÓòÖг£¼ûµÄÌÛÍ´Àà±ð¡¢ÌÛÍ´ÌصãÒÔ¼°Ö§ÅäÉñ¾­

¡¡¡¡´ËÍâ, ÂýÐÔÌÛÍ´»¼ÕßÆÕ±é´æÔÚÏÂÇðÄÔ-´¹Ìå-ÉöÉÏÏÙÖá (HPAÖá) µÄ¹¦ÄÜʧµ÷[17]¡£¶øHPAÖá×÷ΪÖ÷ÒªµÄÓ¦¼¤·´Ó¦ÏµÍ³, ÆäÖ÷ÒªµÄ×÷ÓÃÊǼ¤»îÏÂÓεÄƤÖÊ´¼²úÉú[18], ËùÒÔÈç¹ûHPAÖáµÄ¹¦ÄÜ·¢Éúʧµ÷¿ÉÄܻᵼÖÂƤÖÊ´¼Ë®Æ½µÄ½µµÍ¡£Ñо¿·¢ÏÖÔÚһЩÂýÐÔÌÛÍ´¼²²¡µÄ»¼ÕßѪÇåÖÐ, ÆäƤÖÊ´¼Ë®Æ½Ã÷ÏÔ½µµÍ, °üÀ¨EMs¡¢ÂýÐÔÅèǻʹ×ÛºÏÕ÷µÈ, ¶ø¼Ì·¢ÐÔµÄƤÖÊ´¼·ÖÃÚ¼õÉÙÓֿɼÓÖØÌÛÍ´¡£VincentµÈ[19]Ñо¿·¢ÏÖ, Í´¾­»¼ÕߵĻúÌåƤÖÊ´¼Ë®Æ½Óë¸Ã»¼ÕßµÄÍ´¾­²¡³ÌÖ®¼ä³Ê¸ºÏà¹Ø, ÌáʾHPAÖáµÄ¹¦ÄÜÊܵ½ÒÖÖÆ¿ÉÄÜÊÇÂýÐÔÌÛÍ´µÄ¼Ì·¢½á¹ûÖ®Ò»¡£

¡¡¡¡¾¡¹ÜÄ¿Ç°ÔÝʱ»¹ÎÞ·¨È·¶¨ÖÐÊàÉñ¾­ÏµÍ³µÄ±ä»¯ÄÜ·ñÓ°ÏìÌÛÍ´µÄ״̬¼°Æä¾ßÌåµÄ»úÖÆ[20], µ«Ä¿Ç°¿ÉÒÔÃ÷È·µÄÊÇÖÐÊàÉñ¾­ÏµÍ³µÄ±ä»¯È·Êµ¿ÉÒÔ¼ÓÖØÂýÐÔÌÛÍ´µÄÖ¢×´, ͬʱҲʹ»¼Õ߶ÔÆäËûÂýÐÔÌÛÍ´¼²²¡µÄÒ׸ÐÐÔ¸üÇ¿¡£

¡¡¡¡2.2 ϸ°ûÒò×ÓºÍÍâÖÜÉñ¾­ÏËάµÄÏ໥×÷ÓÃ

¡¡¡¡Ä¿Ç°¹ØÓÚEMs³ÊÏÖ³öµÄ»úÌåËðÉËÇé¿ö¼°ÆäÌÛÍ´µÄÖ±½ÓÏà¹ØÐÔÑо¿»¹·Ç³£ÉÙ, ÓÐÑо¿ÏÔʾ54%µÄÅèǻʹ»¼Õ߶¼±»Õï¶ÏÓÐEMs[21]¡£ÓÐÑо¿±íÃ÷EMsµÄÁÙ´²±íÏÖ°üÀ¨ÂýÐÔÅèǻʹµÈ[22]¡£³ýÁËÇ°ÊöµÄÖÐÊàÉñ¾­ÏµÍ³ºÍÌÛÍ´Ö®¼äµÄ¹Øϵ, ¶ÔÓÚÉñ¾­ÖáÍ»ÓëÌÛÍ´µÄ¹ØϵÑо¿¸üÉÙ¡£ÓÐÑо¿±íÃ÷EMs¿ÉÒÔÌá¸ß¸¹Ä¤Ç»ÖеĴÙÑ×Òò×Ó¡¢Ç÷»¯Òò×Ó¡¢Éú³¤Òò×Óˮƽ¡£ZhangµÈ[23]Ò²·¢ÏÖ¾ÞÊÉϸ°ûÒƶ¯ÒÖÖÆÒò×Ó¡¢È±ÑõÓÕµ¼Òò×Ó¡¢Ñª¹ÜÄÚƤÉú³¤Òò×ӵȿÉÒÔÔ¤²âEMsµÄ½×¶Î¡£ÔÚ¶¯Îï¼¹±³Éñ¾­½ÚµÄÅàÑøʵÑéÖÐ, ½øÒ»²½Ö¤ÊµÁËÑ×Ö¢Òò×Ӵ̼¤ÍâÖÜÉñ¾­µÄÌÛÍ´Ãô¸ÐÐÔ¡£

¡¡¡¡EMs»¼Õߵĸ¹Ä¤Òº (PF) ÖеÄÖî¶à·Ö×ÓŨ¶ÈÉý¸ßÓëÌÛÍ´Ö±½ÓÏà¹Ø, Èç¹ýÑõ»¯ÎïøÌåÔöÖ³ÎD»îÊÜÌåγ (PPAR-γ) ÓëÐÔ½»À§ÄÑ¡¢Í´¾­³ÊÕýÏà¹Ø¡£EMs»¼Õßͨ¹ý´ÙÐÔÏÙ¼¤ËØÊͷż¤ËØÀàËÆÎï (GnRH-a) ÖÎÁƺó, PFÖа×ϸ°û½éËØ8 (IL-8) ¡¢ÈÑÉïÏà¹Øµ°°×A (PAPP-A) ¡¢Ôм¤ËØÏà¹Ø×Ó¹¬ÄÚĤµ°°× (PAEP) ¡¢Éú³¤¼¤ËشٷÖÃÚËØ (MK) ˮƽµÄÏÔ׿õµÍÓëÌÛÍ´Ò²ÓйØÁª, ÍƲâһЩÌØÒìÐÔ·Ö×Ó²ÎÓë½éµ¼ÁËÍ´¾õÉñ¾­µÄ´«µ¼, ÈçÖ×Áö»µËÀÒò×Óα (TNF-α) ÓëÍ´¾­ÕýÏà¹Ø, IL-1βÔÚEMs¡¢ÂýÐÔÅèǻʹ»¼ÕßÖеÄˮƽÏÔ×ÅÉý¸ß¡£´ËÍâ, һЩÇ÷»¯Òò×ÓÒ²¿ÉÒÔͨ¹ý¸÷ÖÖ;¾¶²ÎÓëÉñ¾­Ñ×Ö¢¹ý³Ì, Èçµ¥ºËϸ°ûÇ÷»¯µ°°×1 (MCP-1) [24]¡£ÔÚ´ÓSD´óÊóÖзÖÀë³öµÄ±³¸ù½Ú (DRG) Éñ¾­Ôª×÷Ϊ¾­µäµÄÉñ¾­ÌÛÍ´Ñо¿Ä£ÐÍÖÐ, MCP1¼°ÆäÊÜÌåϸ°û±íÃæÇ÷»¯Òò×ÓÊÜÌå2 (CCR2) Ũ¶ÈÉý¸ß, ¶øÇÒµ÷½Ú»î»¯µ°°× (RANTES) ¿ÉÌá¸ßCa2+ͨµÀµçÁ÷, ÍƲâһЩÇ÷»¯Òò×ÓÓë¸Ð¾õÉñ¾­ÔªÖ®¼ä¿ÉÄÜ´æÔÚÏ໥×÷Óá£

¡¡¡¡Éñ¾­Éú³¤Òò×Ó (NGF) ÊÇÒ»ÖÖ´«Í³µÄÉñ¾­ÓªÑøÒò×Ó, ÓÐÁ½ÖÖĤÊÜÌå½éµ¼ÆäÐźÅ, ·Ö±ðΪ¸ßÇ׺͵ÄÀÒ°±Ëἤø (TrkA) ÊÜÌåºÍµÍÇ׺͵Äp75NTRÊÜÌå[25]¡£NGFÔÚEMsÖбí´ï, TrkAÊÜÌåÒ²Èç´Ë, ÌرðÊÇÔÚ¹¬÷¾ÈÍ´øÉ½þÈóÐÍ×Ó¹¬ÄÚĤÒìλ½á½Ú (DIE) ËðÉËÖи߶ȱí´ï¡£EMs»¼ÕßµÄPFÖÐNGFÒ²ÏÔ×űí´ï¡£TNF-αºÍIL-1β´¦ÀíÈË×Ó¹¬ÄÚĤÉÏƤϸ°û (hEECs) ºó, ´Ù½øNGF·ÖÃÚ, È»¶øNGFµÄmRNAת¼ˮƽûÓз¢ÉúÃ÷ÏԵı仯¡£

¡¡¡¡ÔÚÌÛÍ´¹ý³ÌÖÐ, һЩ·Ç´«Í³µÄϸ°ûÒò×ÓÒ²²ÎÓëÑ×Ö¢·´Ó¦¹ý³Ì, ÈçPAEP×÷ΪһÖÖÌǵ°°×²ÎÓëÔ¾­ÌÛÍ´, ÊÝËØ (Leptin) ²ÎÓëEMs»¼ÕߵĹÇÅèÌÛÍ´[26]¡£

¡¡¡¡2.3 Ñ×Ö¢Òò×Ó½µµÍÍâÖÜÉñ¾­µÄÃô¸ÐÐÔ

¡¡¡¡Ñ×Ö¢Òò×Óͨ¹ý½áºÏµ½Éñ¾­ÔªµÄÌÛÍ´¸ÐÊÜÆ÷ (Nociceptors) ÉÏ, ´Ì¼¤Ï¸°ûÖÐת¼-·­ÒëÏà¹ØµÄÐźÅͨ·¡£EMs»¼ÕßµÄÒìλ×éÖ¯ÖеÄ˲ʱ¸ÐÊÜÆ÷µçλÏã²ÝËáÊÜÌå1 (TRPV1) ±í´ïºÍmRNAˮƽ±ÈÕý³£ÈË×éÖ¯¸ß¡£ÓÐÑо¿±íÃ÷TNF-αºÍMCP-1ͨ¹ýTRPV1Ó°Ïì¸Ð¾õÉñ¾­ÔªµÄĤµçλ±ä»¯, ¼¤»î°ûÄÚ¼¤Ã¸¡£ÔÚ»¼ÓÐEMsµÄÇé¿öÏÂ, ÂýÐÔÌÛÍ´¼´±»¼¤Æð¡£

¡¡¡¡µçѹÃÅ¿ØÄÆÀë×ÓͨµÀ¹²°üº¬9ÖÖÑÇÐÍ (Nav1.1¡«Nav1.9) , ÓÉÄÆÀë×ÓͨµÀ (SCNA) »ùÒò±í´ï, ÓÉĤµçλ¼¤»îºÍÒÖÖÆ¡£EMs»¼Õ߸߱í´ï¸Ã»ùÒò, ÔÚSD DRGÄ£ÐÍÖÐ, TNF-α´Ù½øNav1.3 (SCNA3) ºÍNav1.8 (SCN10A) Á½ÖÖÄÆÀë×ÓͨµÀ±í´ï, Ìá¸ßNav1.8µÄµçѹ¡£ÔÚÔ­´ú¸Ð¾õÉñ¾­ÔªÖÐ, MCP-1ͨ¹ý¼¤»îÁ×Ö¬õ£¼¡´¼3¼¤Ã¸-µ°°×¼¤Ã¸B (PI3K-Akt) ÐźÅͨ·, Ìá¸ßNav1.8µÄ»îÐÔ, ͨ¹ýCCR2/Èý¾ÛÌåGµ°°×βγ (Gβγ) ²¢Éϵ÷TRPV1ºÍNava1.8µÄ±í´ïˮƽ¡£

¡¡¡¡ÖÐÊàÉñ¾­Ãô»¯ºÍ¸Ð¾õÉñ¾­Ôª³ÖÐøÊܵ½Ñ×Ö¢Òò×ӵĴ̼¤¶¼»áÌá¸ßÖÐÊàÉñ¾­ÏµÍ³µÄÍ´¾õÃô¸ÐÐÔ¡£Ñо¿±íÃ÷¶ÔÓÚEMs»¼Õß, PFÖÐTNF-α¡¢PAEP¡¢¹Ç±£»¤ËØ (OPG) ¡¢MCP1µÄŨ¶ÈÉý¸ßÊÇÒýÆðÌÛÍ´µÄÉñ¾­µçÉúÀíºÍÉñ¾­ÎïÀíµÄÏà¹ØÖ¸±ê¡£

¡¡¡¡2.4 ÄÆÀë×ÓͨµÀ½éµ¼Éñ¾­ÔªÌÛÍ´ÐźŵĴ«µ¼

¡¡¡¡µçѹÃÅ¿ØÄÆÀë×ÓͨµÀÊÇÒ»ÖÖÓëÐË·Ü´«µ¼ºÍÐźŴ«µ¼ÓÐ×ÅÃÜÇйØϵµÄ¹Ø¼üµ°°×, Ö÷ÒªÓ붯×÷µçλµÄÉÏÉýÖ§Óйء£Ä¿Ç°·¢ÏÖµçѹÃÅ¿ØÄÆÀë×ÓͨµÀ¹²°üº¬9ÖÖÑÇÐÍ (Nav1.1¡«Nav1.9) , ÖÐÊàÉñ¾­ÏµÍ³ºÍÍâÖÜÉñ¾­ÏµÍ³¾ùÓиõ°°×·Ö²¼[27]¡£ÓÐÑо¿±íÃ÷Nav1.3¡¢Nav1.8ºÍNav1.9ÔÚÌÛÍ´µÄ±í´ï¹ý³ÌÖпÉÄÜ·¢»ÓÁËÒ»¶¨×÷ÓÃ[28]¡£

¡¡¡¡ÓÎÀëµÄÉñ¾­Ä©ÉÒ×÷Ϊʹ¾õµÄ¸ÐÊÜÆ÷, ºÜ¶àѧÕ߶¼Ö§³ÖÆä¾ßÓÐÌØÒìÐԵĹ۵㡣×é°·×÷ΪһÖÖ×ÔÈ»´Ì¼¤Îï¿ÉÒÔÒýÆðÈ˵ĻúÌå²úÉúÍ´¾õ, ÆäÖ÷ÒªµÄ×÷ÓûúÖÆΪµ±»úÌåµÄij¸ö²¿Î»Êܵ½É˺¦Ê±, »á´Ì¼¤µ½¸Ã²¿Î»µÄϸ°ûÊÍ·Å×é°·µÈÏà¹ØÎïÖÊ, ÕâЩÊͷŵÄÎïÖÊÓëÉñ¾­Ä©ÉÒÏ໥×÷ÓÃ, ͨ¹ýÉñ¾­Ä©ÉÒ½øÐÐÉ˺¦ÐԴ̼¤´«µ¼, ÕâЩ´Ì¼¤µÄ´«Èë»áÒýÆð¼¹Ëè±³½ÇµÄ¹È°±ËáµÈÎïÖʵÄÊÍ·Å, ¹È°±ËáµÈÎïÖÊÓëÏàÓ¦µÄÊÜÌå½áºÏÖ®ºó»á´Ì¼¤Ca2+ͨµÀ, »áÒýÆðCa2+Ũ¶ÈµÄÌá¸ß, ¼¤»îÏà¹ØøÀà, ÕâЩøÀàµÄÖ÷Òª×÷ÓÃÊǼ¤»îÐźŴ«µ¼ÏµÍ³²úÉú»îÐÔÎïÖÊ, ×îÖÕµ¼Ö»úÌåÍ´¾õµÄ²úÉú¡£ÀýÈçÔÚ¼¤»îÒ»Ñõ»¯µªºÏ³Éø (NOS) ºó, ¿ÉÒÔÉú³ÉNO, ¶øÒÖÖÆ»ò¼¤»îNO/»·ÄñÜÕËá (cGMP) ϵͳºó»á¶ÔÂð·ÈµÄÕòÍ´×÷ÓÃÆ𵽶Կ¹»òÕßÔöÇ¿µÄ×÷Ó᣻¹ÓÐÒ»ÖÖÍ´¾õ²úÉú»úÖÆΪ×éÖ¯Êܵ½´Ì¼¤ºó, ATP×ÔËðÉËϸ°ûµÄ°ûÖʻᷢÉú±ä»¯, Ïòϸ°ûÍâÊÍ·Å, ÕâЩ°ûÖÊ»á´Ì¼¤ATPÃÅ¿ØÀë×ÓͨµÀP2X-2/3ÊÜÌå»òATPÃÅ¿ØÀë×ÓͨµÀP2X3ÊÜÌå, ´Ó¶ø»áµ¼Ö¸оõÉñ¾­Ä©ÉÒ·¢ÉúÈ¥¼«»¯, ʹ¸Ð¾õÉñ¾­ÔªµÄ·ÅµçЧ¹ûÌá¸ß, ËùÒÔÔÚÉñ¾­Ôª´«ÈëÖÐÊàºó»úÌå»á¸Ðµ½ÓÐÇ¿ÁÒµÄÍ´¾õ¡£ÁíÒ»ÖÖÉñ¾­µÝÖʵ¼ÖÂÍ´¾õµÄ»úÖÆ, ¼´ÔÚÖÐÊàÉñ¾­ÏµÍ³´«µ¼Í´¾õ¹ý³ÌÖеÄÉñ¾­µÝÖÊ¿ÉÄÜÊÇÒ»ÖÖ¾ßÓÐÂð·ÈÑù»îÐÔµÄëÄÀàÎïÖÊ, ¿ÉÄÜΪ°¢Æ¬ëÄ, ÆäÖ÷Òª°üº¬3ÖÖÀàÐÍ, ·Ö±ðΪǿ·ÈëÄ¡¢ÄÔ·ÈëĺÍβ-ÄÚ·ÈëÄ, ÕâЩ°¢Æ¬ëÄÔÚÓëÏà¹ØÊÜÌå½áºÏºó»á¼¤»îÏÙÜÕËá»·»¯Ã¸µÄ»îÐÔ, ´Ó¶øʹÖÐÊàÉñ¾­Ôª¼¤»î²¢ÇÒµ¼ÖÂÍ´¾õ´«ÈëµÄÈ¥¼«»¯, ×îÖÕ»áÈûúÌå¸ÐÊܵ½Í´¾õ¡£Òò´Ë, ÓÐѧÕßÈÏΪ×é°·ÄÜϵͳÊÇ¿ª·¢ÐÂÐÍÕòÍ´Ò©µÄÒ»¸öз½·¨[29]¡£

¡¡¡¡2.5 Éñ¾­ÔªµÄ¼¤Ã¸ÐźŴ«µ¼Í¨Â·¼¤»î

¡¡¡¡Ë¿ÁÑÔ­»î»¯µ°°×¼¤Ã¸ (MAPK) ²ÎÓëÁË»úÌåµÄϸ°ûÄÚÐźŵĴ«µ¼¹ý³Ì, ¶øÓÐÑо¿Ö¤ÊµÕâÖÖÐźŴ«µ¼¹ý³ÌÓë»úÌåµÄÑ×ÐÔ·´Ó¦ÒÔ¼°Éñ¾­ÔªµÄ¿ÉËÜÐԵȶ¼´æÔÚ×ÅÖØÒªµÄ¹ØÁª¡£Ä¿Ç°ÔÚ²¸È鶯ÎïµÄÌåÄÚ, ·¢ÏÖÁË3ÖÖMAPKÀàÐÍ, ·Ö±ðΪϸ°ûÍâµ÷½Úµ°°×¼¤Ã¸ (ERK) ¡¢p38 MAPKºÍc-Jun°±»ùÄ©¶Ë¼¤Ã¸ (c-Jun NH2-teminal kinase, JNK) [30]¡£MAPKÔÚ»úÌåÍ´¾õ²úÉú¹ý³ÌµÄÖ÷Òª»úÖÆΪÔÚÊܵ½ËðÉ˺ó, MAPKµÄ3ÖÖÀàÐͼ´ERK¡¢p38MAPKºÍJNK»á·Ö±ðÔÚ²»Í¬µÄϸ°ûÖб»¼¤»î, ÆäÖÐp38 MAPKÖ÷ÒªÊÇС½ºÖÊϸ°û[31], JNKΪÐÇÐÍϸ°û, ¶øERKÔòÔÚÁ½ÖÖϸ°ûÖоù±»ÒÀ´Î¼¤»î[32]¡£MAPK¼Ò×åÔÚϸ°ûÖб»¼¤»îºó»áʹÉ˺¦ÐźŵĴ«µ¼·¢Éú±ä»¯, ´Ó¶øµ¼Ö»úÌå¸ÐÊܵ½Í´¾õ¡£Ñо¿ÏÔʾºÜ¶àÖÖÍâÖÜÉñ¾­ËðÉ˶¼¿ÉÒÔ¼¤»î¼¹ËèºÍС½ºÖÊϸ°ûµÄ3ÖÖÀàÐ͵ÄMAPK, °üÀ¨Éñ¾­²¡ÀíÐÔÌÛÍ´¡¢°©ÐÔ»òÕßÑ×ÐÔÌÛÍ´, Ïà·´, Èç¹û¶ÔÕâЩ¼¤»îµÄͨ·½øÐÐÒÖÖÆÔò»á»º½âÑо¿ÖеĶ¯ÎïÄ£ÐÍÌÛÍ´¡£Õë¶ÔÓÚÕâЩÑо¿½á¹û, ¿ÉÒÔ½«ÕâЩ;¾¶×÷ΪÖÎÁÆÌÛÍ´µÄÍ»ÆÆ·½Ïò¡£

¡¡¡¡3 ½áÓï

¡¡¡¡Å®ÐÔÂýÐÔÅèǻʹÊÇÒ»ÖÖ³£¼ûÓÖ¸´Ôӵļ²²¡¡£ÂýÐÔÅèǻʹµÄÌÛÍ´Ò׸ÐÐÔ²»½öÓëÖÐÊàÉñ¾­ÏµÍ³µÄÉñ¾­Ó°Ïñѧ±ä»¯ÓйØ, »¹ÓëÑ×֢ϸ°û¼°ÆäÒò×ÓÃÜÇÐÏà¹Ø, ²¢ÇÒÏ໥×÷Óá£ÆäÖÐ, ¸÷ÖÖϸ°ûºÍÑ×Ö¢Òò×ӽ鵼ÌÛÍ´ÐźŹؼü·Ö×ÓÊǸ÷ÖÖÀë×ÓͨµÀÊÜÌå, µçѹÃÅ¿ØÄÆÀë×ÓͨµÀµÄ¼¤»îºÍ¹Ø±ÕÖ±½ÓÓ°ÏìÌÛÍ´³Ì¶ÈµÄÖÜÆÚ¡£Òò´Ë, Àë×ÓͨµÀÏà¹ØµÄС·Ö×ÓÒ©Îï³£ÓÃÀ´½øÐÐÂýÐÔÅèǻʹµÄ¸¨ÖúÖÎÁÆ, ¹ÊºÏÀíµØÕï¶ÏºÍÆÀ¹ÀÂýÐÔÅèǻʹÊǵ±Ç°ÁÙ´²¹¤×÷µÄÖ÷ÒªÀ§ÄÑÖ®Ò»¡£¼ò¶øÑÔÖ®, ¸÷ÖÖ¸¾¿Æ¼²²¡µÄÂýÐÔÑ×Ö¢»·¾³³ÖÐø´Ì¼¤ÖÐÊàÉñ¾­ÏµÍ³ºÍÍâÖÜÉñ¾­ÏµÍ³, »áÖ±½Ó»ò¼ä½ÓµØÓÕµ¼ÂýÐÔÌÛÍ´, ¶øÇÒÌÛÍ´±¾ÉíÒ²»áÑÓ³¤¸÷ÖÖ¸¾¿Æ¼²²¡µÄ²¡³Ì¡£±ÈÈçEMsµÄÉñ¾­Ñ×Ö¢Òò×ÓËÙ¼¤ëÄPÎïÖÊ (substance P, SP) ½éµ¼Éñ¾­µÄÍ´¾õ¹ý³Ì, ²ÎÓëÖÐÊàÉñ¾­ÏµÍ³ºÍ¼²²¡ÐźŽ»²æ¶Ô»°¡£ÕâÖÖ³¤ÆÚµÄÍâÖÜÉñ¾­Í´¾õÃô»¯×îÖջᵼÖÂÖÐÊàÉñ¾­ÏµÍ³µÄ¸Ä±ä, ±ÈÈçÂýÐÔÅèǻʹ»¼ÕߵĻÒÖÊÃܶÈÉý¸ßµÈÏÖÏó¡£

¡¡¡¡Ä¿Ç°, ¸¾¿Æ¼²²¡µÄÌÛÍ´¼°ÆäÏà¹ØÉñ¾­ÉúÎïѧ»úÖƵÄÑо¿ÎÄÏ×ÈÔÈ»·Ç³£ÉÙ¡£ËäÈ»µ±Ç°ÒѾ­·¢ÏÖÍ´¾õÉñ¾­ÖеÄһЩ»ùÒòµÄ±í´ï±ä»¯, µ«ÊÇÑ×Ö¢Òò×ӶԸоõÉñ¾­ÔªµÄ×÷ÓûúÖÆ»¹²»Çå³þ¡£Ñ°ÕÒ²¢²ûÊöÇå³þÄÄЩÌØÒìÐÔÒò×Óµ¼ÖÂÉñ¾­ÌÛÍ´Ãô¸ÐºÍÌÛÍ´¶ÔÓÚÁÙ´²Õï¶ÏºÍÖÎÁƷdz£ÖØÒª¡£Ä¿Ç°Ìá¸ßGnRH-aˮƽÊÇ»º½âһЩŮÐÔ¸¾¿ÆÌÛÍ´µÄÓÐЧ·½·¨, µ«ÊÇ¿ª·¢³ö·Ç¼¤ËØÒ©Îï¶ÔÓÚδÉúÓýµÄ»¼Õß¾ßÓÐÖØ´óÒâÒå¡£ÔÚÁÙ´²Êµ¼ùÖз¢ÏÖ, ¸¾¿Æ¼²²¡²¡ÔîÈ¥³ýºÍ¸ÄÉƺó, ²¢Î´ÄÜÓÐЧ¸ùÖθ¾¿ÆÌÛÍ´¡£ËùÒÔ, ²»½öÒªÌá¸ß¸¾¿Æ¼²²¡µÄÖÎÁÆ·½°¸, »¹ÒªÁ˽âÇå³þ¸¾¿ÆÌÛÍ´µÄÏà¹ØÉñ¾­ÉúÎï»úÖÆ, ´Ó¸ù±¾ÉÏ×èÖ¹¼²²¡µÄ·¢Éú, ʹÑ×Ö¢Òò×ÓÊͷżõÉÙ, Çжϸ¾¿ÆÌÛÍ´µÄÐźÅͨ·¡£

¡¡¡¡²Î¿¼ÎÄÏ×£º

¡¡¡¡[1] Da Luz RA, de Deus JM, Conde DM.Quality of life and associated factors in Brazilian women with chronic pelvic pain[J].J Pain Res, 2018, 11:1367-1374.
¡¡¡¡[2] Dybowski C, L?we B, Brünahl C.Predictors of pain, urinary symptoms and quality of life in patients with chronic pelvic pain syndrome (CPPS) :A prospective 12-month follow-up study[J].JPsychosom Res, 2018, 112:99-106.
¡¡¡¡[3] Sewell M, Churilov L, Mooney S, et al.Chronic pelvic pain-pain catastrophizing, pelvic pain and quality of life[J].Scand J Pain, 2018, 18 (3) :441-448.
¡¡¡¡[4] Fuentes-Márquez P, Rodríguez-Torres JR, Valenza MC, et al.Balance ability and posture in postmenopausal women with chronic pelvic pain[J].Menopause, 2018, 25 (7) :783-788.
¡¡¡¡[5] Hunter CW, Yang A.Dorsal Root Ganglion Stimulation for Chronic Pelvic Pain:A Case Series and Technical Report on a Novel Lead Configuration[J].Neuromodulation, 2018.[Epub ahead of print]
¡¡¡¡[6]ÃϽÜ, ºéÀò, Áõ³É, µÈ.ÉúÎï·´À¡µç´Ì¼¤ÁªºÏ¸¹Ï´ÔÁ¬Ðø×èÖÍÖÎÁÆÅ®ÐÔÂýÐÔÅèǻʹµÄÁÆЧ¹Û²ì[J].ʵÓÃҽѧÔÓÖ¾, 2018, 34 (4) :579-582.
¡¡¡¡[7] Allaire C, Williams C, Bodmer-Roy S, et al.Chronic pelvic pain in an interdisciplinary setting:1-year prospective cohort[J].Am JObstet Gynecol, 2018, 218 (1) :114.e1-114.e12.
¡¡¡¡[8]³ÂÀöƼ, Ô¬¾ý÷, Ì·»ªµÙ.ÖÐÒ½ÁªºÏµç´Ì¼¤ÖÎÁÆÅ®ÐÔÑ×ÐÔÂýÐÔÅèǻʹµÄÁÙ´²Ñо¿[J].ÏÖ´úÖÐÎ÷Ò½½áºÏÔÓÖ¾, 2016, 25 (14) :1521-1523.
¡¡¡¡[9] Duh K, Funaro MG, DeGouveia W, et al.Crosstalk between the immune system and neural pathways in interstitial cystitis/bladder pain syndrome[J].Discov Med, 2018, 25 (139) :243-250.
¡¡¡¡[10]¸¶Ïþö©, Ò¦ÀöÑÞ, Íõ»¢.×Ó¹¬ÄÚĤÒìλ֢²¡ÔîÓëÅèÇ»ÌÛÍ´µÄÏà¹ØÐÔÑо¿[J].н®Ò½Ñ§, 2018, 48 (3) :291-294.
¡¡¡¡[11] Grinberg K, Granot M, Lowenstein L, et al.A common pronociceptive pain modulation profile typifying subgroups of chronic pelvic pain syndromes is interrelated with enhanced clinical pain[J].Pain, 2017, 158 (6) :1021-1029.
¡¡¡¡[12]»ÆÔ½¿, ³ÂÓѹú, ºîÎĽÜ.¸¹Ç»¾µÁªºÏ¿µ¸¾Ñ×½ºÄÒÖÎÁÆÊäÂѹÜÂѳ²ÄÒÖ׺ϲ¢ÂýÐÔÅèǻʹµÄÁÙ´²¹Û²ì[J].ÊÀ½çÖÐÎ÷Ò½½áºÏÔÓÖ¾, 2018, 13 (5) :666-669.
¡¡¡¡[13]ÀîÊé¾°, ÅíÑÞÆ·, ¼§´ÏîÎ, µÈ.¸¹²¿ÍâÒõÅèµ×¼¡ÈºË«²à¸½¼þ×Ó¹¬÷¾¹ÇÈÍ´øѹÁ¦ÐÔÌÛÍ´ãÐÖµ¶ÔÓÚÂýÐÔÅèǻʹ»¼ÕßµÄÁÙ´²ÒâÒå[J].ɽÎ÷Ò½Ò©ÔÓÖ¾, 2018, 47 (5) :537-539.
¡¡¡¡[14] Woolf CJ, Salter MW.Neuronal plasticity:increasingthe gain in pain[J].Science, 2000, 288:1765-1769.
¡¡¡¡[15]As-Sanie S, Harris RE, Napadow V, et al.Changes in regional gray matter volume in women with chronic pelvic pain:a voxel-based morphometry study[J].Pain, 2012, 153 (5) :1006-1014.
¡¡¡¡[16]Mckinnon BD, Bertschi D, Bersinger NA, et al.Inflammation and nerve fiber interaction in endometriotic pain[J].Trends Endocrin Met, 2015, 26 (1) :1-10.
¡¡¡¡[17] Pierce AN, Christianson JA.Stress and chronic pelvic pain[J].Prog Mol Biol Transl Sci, 2015, 131:509-535.
¡¡¡¡[18] Eller-Smith OC, Nicol AL, Christianson JA.Potential Mechanisms Underlying Centralized Pain and Emerging Therapeutic Interventions[J].Front Cell Neurosci, 2018, 12:35.
¡¡¡¡[19]Vincent K, Warnaby C, Stagg CJ, et al.Dysmenorrhoea is associated with central changes in otherwise healthy women[J].Pain, 2011, 152 (9) :1966-1975.
¡¡¡¡[20] Beazley-Long N, Durrant AM, Swift MN, et al.The physiological functions of central nervous system pericytes and a potential role in pain[J].F1000Res, 2018, 7:341.
¡¡¡¡[21] Trutnovsky G, Plieseis C, Bjelic-Radisic V, et al.Vulvodynia and chronic pelvic pain in a gynecologic outpatient clinic[J].J Psychosom Obstet Gynaecol, 2018:1-5.
¡¡¡¡[22]»ÆÑÞ»Ô, ³óµ¤, ·ëµ¤, µÈ.ξ­Ö¹Í´·½¶Ô×Ó¹¬ÄÚĤÒìλ֢ģÐÍ´óÊó×ÔÊÈ»ùÒòBeclin-1¡¢LC3±í´ïµÄÓ°Ïì[J].¹ãÖÝÖÐÒ½Ò©´óѧѧ±¨, 2018, 35 (5) :848-854.
¡¡¡¡[23] Zhang F, Liu XL, Wang W, et al.Expression of MMIF, HIF-1αand VEGF in Serum and Endometrial Tissues of Patients with Endometriosis[J].Curr Med Sci, 2018, 38 (3) :499-504.
¡¡¡¡[24] Plaschke K, Schulz S, Rullof R, et al.In-depth characterization of the neuroinflammatory reaction induced by peripheral surgery in an animal model[J].J Neural Transm (Vienna) , 2018, 125 (10) :1487-1494.
¡¡¡¡[25] Mitsiadis TA, Pagella P.Expression of Nerve Growth Factor (NGF) , TrkA, and p75 (NTR) in Developing Human Fetal Teeth[J].Front Physiol, 2016, 7:338.
¡¡¡¡[26] Chmaj-Wierzchowska K, Kampioni M, Wilczak M, et al.The role of chemokine and non-chemokine factors in pain-related complaints in patients with endometrial cysts[J].Ginekol Pol, 2015, 86 (2) :94-99.
¡¡¡¡[27] Patel F, Brackenbury WJ.Dual roles of voltage-gated sodium channels in development and cancer[J].Int J Dev Biol, 2015, 59 (7/8/9) :357-366.
¡¡¡¡[28] Chen KH, Yang CH, Wallace CG, et al.Combination therapy with extracorporeal shock wave and melatonin markedly attenuated neuropathic pain in rat[J].Am J Transl Res, 2017, 9 (10) :4593-4606.
¡¡¡¡[29] Popiolek-Barczyk K, Lazewska D, Latacz G, et al.Antinociceptive effects of novel histamine H3 and H4 receptor antagonists and their influence on morphine analgesia of neuropathic pain in the mouse[J].Br J Pharmacol, 2018, 175 (14) :2897-2910.
¡¡¡¡[30] Hao Y, Feng Y, Li J, et al.Role of MAPKs in HSP70′s Protection against Heat Stress-Induced Injury in Rat Small Intestine[J].Biomed Res Int, 2018, 2018:1571406.
¡¡¡¡[31]ÒüÒÕÈå, Ã×Åôϼ, ÕÅÓî, µÈ.PÎïÖÊͨ¹ýp38MAPK;¾¶¼¤»îС½ºÖÊϸ°û²ÎÓë´óÊóÈÈÍ´Ãô¸ÐµÄÐγÉ[J].ɽÎ÷Ò½¿Æ´óѧѧ±¨, 2018, 49 (7) :785-789.
¡¡¡¡[32]¶ÅÑÞ, ÍõºÆ½­, ËÕºìÁÁ, µÈ.l-ËÄÇâ°ÍÂíÍ¡¶ÔÂÈ°·ÍªÒÀÀµ´óÊóº£ÂíGFAP¼°·ü¸ôºËERKÁ×Ëữµ°°×±í´ïµÄÓ°Ïì[J].Öйú·¨Ò½Ñ§ÔÓÖ¾, 2018, 33 (3) :258-262.

×÷Õßµ¥Î»£ºÕã½­Ê¡º£ÄþÊÐÖÐÐÄÒ½Ôº¸¾²ú¿Æ Õã½­´óѧҽѧԺ¸½Êô¸¾²ú¿ÆÒ½Ôº
Ô­Îijö´¦£ºÁõÑÞÃô,½­ÐãÐã.Å®ÐÔÂýÐÔÅèǻʹµÄÉñ¾­ÉúÎïѧÑо¿½øÕ¹[J].¹ú¼Ê¸¾²ú¿ÆѧÔÓÖ¾,2019,46(01):32-36.
Ïà¹Ø±êÇ©£º
  • ±¨¾¯Æ½Ì¨
  • ÍøÂç¼à²ì
  • ±¸°¸ÐÅÏ¢
  • ¾Ù±¨ÖÐÐÄ
  • ´«²¥ÎÄÃ÷
  • ³ÏÐÅÍøÕ¾